Exozymes Inc. has announced new scientific research results from its 100-liter pilot production run of NCT, utilizing its AI-enhanced enzymes, known as exozymes. According to the company, performance of the cell-free biomanufacturing process improved as the reaction scale increased, with higher recovery, isolated yield, and pharmaceutical-grade purity achieved at larger volumes. The pilot run, independently executed by Cayman Chemical using a technology transfer package from Exozymes, marks the first full end-to-end operation of the exozyme-based process by an external partner, demonstrating both protocol transferability and operational robustness. These results have been reported and expand upon previously announced scale-up milestones, with high-purity NCT now available for commercial formulation development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.